CN1282484C - 一种降脂药物组合物 - Google Patents

一种降脂药物组合物 Download PDF

Info

Publication number
CN1282484C
CN1282484C CNB021351406A CN02135140A CN1282484C CN 1282484 C CN1282484 C CN 1282484C CN B021351406 A CNB021351406 A CN B021351406A CN 02135140 A CN02135140 A CN 02135140A CN 1282484 C CN1282484 C CN 1282484C
Authority
CN
China
Prior art keywords
propolis
blood fat
coa
parts
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021351406A
Other languages
English (en)
Other versions
CN1465399A (zh
Inventor
邓志强
逯传凤
吕迎智
张坤镛
孙启玉
吕明明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chen Xingxing
Zhang Kunyong
Baolingbao Biology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB021351406A priority Critical patent/CN1282484C/zh
Publication of CN1465399A publication Critical patent/CN1465399A/zh
Application granted granted Critical
Publication of CN1282484C publication Critical patent/CN1282484C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明提供一种降脂药物组合物，其中各原料的重量组成为：蜂胶50-90份、酶制剂(COA)5-30份、烟酸2-20份。本发明的独特功效是将三种具有降脂功能物质复合为一体使用，让蜂胶在该制剂中既发挥了降脂的功效，同时又起到了抗氧化剂和肠道pH值调节缓冲剂作用，促进酶制剂(COA)的肠道吸收。降脂调脂剂以调整血脂为主，同时具有降血糖、降血压和抗衰老等功能，和现有技术的同类产品相比，具有使用方便，易于保存，治疗与保健并举的特点，因而，具有很好的推广使用价值。

Description

一种降脂药物组合物
1、技术领域
本发明涉及一种治疗心脑血管疾病的药物，具体地说是一种降血压调整血脂浓度的降脂调脂剂。
2、技术背景
以蜂胶、酶制剂(COA)和烟酸的单体在人体内参与血脂生理代谢时的途径各不相同，因而所产生的效果也不同，比如，蜂胶是蜜蜂采集的脂源性植物经蜜蜂加工调制而成的，在临床上用于多种病症的治疗与保健。蜂胶在临床上应用具有明显的降脂效应和防止胆固醇在血管壁上的沉积作用，并且无毒、无副作用，与其它各种降脂药物相比，表现出降脂疗效持久的特点。高粘滞血症者服用后明显感觉头脑清晰，肢麻现象消失。冠心病患者服用后能防治和延缓动脉硬化、血管狭窄和阻塞作用。烟酸是NAD和NADP两种重要辅酶的组成成分，参与人体碳水化合物、脂肪和蛋白质的代谢，具有维护神经系统、皮肤和消化系统的功能。对扩张末梢血管、促进末梢血管生长方面和降低血脂水平方面有着特殊的作用。酶制剂(COA)是体内乙酰化反应的辅酶，对体内塘、脂质及蛋白质的代谢起着重要作用。对三羧酸循环和肝糖原的积存，对乙酰胆碱的降低及血浆脂质的含量具有调节作用等。酶制剂(COA)通过口服进入人体后的吸收是一个医学界长期来进行探索的课题，虽有一些解决方案，但都不尽人意。
3、发明目的
本发明的目的是提供一种用于调节血脂，它是集蜂胶、酶制剂(COA)和烟酸单体使用的优点制成的一种复合制剂，该制剂在降脂、降糖方面，具有较强的降脂的作用，并且在降血脂同时能有降低血压，改善脂肪肝症状，调整总胆固醇及降低血糖的功效。
本发明的目的是按以下方式实现的，将蜂胶、酶制剂(COA)和烟酸三种具有降脂功能物质复合为一体使用，让蜂胶在该制剂中既发挥了降脂的功效，同时又起到了抗氧化剂和肠道PH值调节缓冲剂作用，促进酶制剂(COA)的肠道吸收。蜂胶与酶制剂(COA)混合进入肠道后，可防止在其被人体吸收之前而不破坏其活性，使酶制剂(COA)充分发挥降血脂及胆固醇的功能。蜂胶中的黄酮类的物质还是酶制剂(COA)还原酶(HMG-COA)的抑制剂，本发明的制剂中规定黄酮物质含量为6.5％以上，由于抑制了(HMG-COA)还原酶的活性，就可以有效地降低胆固醇的生物合成速率，达到降低胆固醇的目的。
本发明的一种降脂药物组合物是由蜂胶、酶制剂(COA)、烟酸混合制成，各原料的重量组成为蜂胶50-90份、酶制剂(COA)5-30份、烟酸2-20份。
本发明的降脂调脂剂中各原料的优选重量组成为：蜂胶70-80份、酶制剂(COA)20-25份、烟酸8-17份。
本发明的降脂调脂剂中各原料的最佳重量组成为：蜂胶75份、酶制剂(COA)13份、烟酸12份。
本发明的降脂调脂剂是药剂学上所说的任一剂型，最好是胶囊、片剂或颗粒剂。
本发明的降脂调脂剂中各原料的制备方法是：a、将蜂胶置于-5至-10℃的低温下冷冻，用冷冻粉碎机粉碎至400目备用；b、酶制剂(COA)按1∶50-100倍量加入异麦芽糖溶液中溶解后，置于-5至-10℃的低温下冷冻粉碎至400目备用。
本发明的降脂调脂剂制备方法是：将蜂胶、酶制剂(COA)、烟酸按比例干混1.5小时后分装胶囊，每粒装0.15g即得产品。
4、实施方式：
配方一、
按重量比称取蜂胶70份、酶制剂(COA)15份、烟酸15份，混合搅拌1.5小时后分装胶囊，每粒装0.15g即得产品。
配方二、
按重量比称取蜂胶85份、酶制剂(COA)7.5份、烟酸7.5份，混合搅拌1.5小时后分装胶囊，每粒装0.15g即得产品。
配方三、
按重量比称取蜂胶90份、酶制剂(COA)5份、烟酸5份，混合搅拌1.5小时后分装胶囊，每粒装0.15g即得产品。
本发明的降脂调脂剂以调整血脂为主，同时具有降血糖、抗衰老等功能，和现有技术的同类产品相比，具有使用方便，易于保存，治疗与保健并举的特点，因而，具有很好的推广使用价值。

Claims (4)

1、一种降脂药物组合物，其特征在于该制剂各原料的重量组成为蜂胶50-90份、COA酶制剂5-30份、烟酸2-20份，制备步骤如下：
a、将蜂胶置于-5至-10℃的低温下冷冻，用冷冻粉碎机粉碎至400目备用；
b、COA酶制剂按1∶50-100倍量加入异麦芽糖溶液中溶解后，置于-5至-10℃的低温下冷冻粉碎至400目备用；
c、将蜂胶、COA酶制剂、烟酸按比例干混1.5小时后分装胶囊，每粒装0.15g即得产品。
2、根据权利要求1所述的一种降脂药物组合物，其特征在于该制剂各原料的重量组成为：蜂胶70-80份、COA酶制剂20-25份、烟酸8-17份。
3、根据权利要求1所述的一种降脂药物组合物，其特征在于该制剂各原料的重量组成为：蜂胶75份、COA酶制剂13份、烟酸12份。
4、根据权利要求1所述的一种降脂药物组合物，其特征在于该制剂是药剂学上所说的胶囊、片剂或颗粒剂。
CNB021351406A 2002-06-25 2002-06-25 一种降脂药物组合物 Expired - Fee Related CN1282484C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021351406A CN1282484C (zh) 2002-06-25 2002-06-25 一种降脂药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021351406A CN1282484C (zh) 2002-06-25 2002-06-25 一种降脂药物组合物

Publications (2)

Publication Number Publication Date
CN1465399A CN1465399A (zh) 2004-01-07
CN1282484C true CN1282484C (zh) 2006-11-01

Family

ID=34146050

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021351406A Expired - Fee Related CN1282484C (zh) 2002-06-25 2002-06-25 一种降脂药物组合物

Country Status (1)

Country Link
CN (1) CN1282484C (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2537242C1 (ru) * 2013-05-07 2014-12-27 Государственное автономное научное учреждение Республики Башкортостан "Центр аграрных исследований" Ректальные суппозитории с никотиновой кислотой и экстрактом прополиса

Also Published As

Publication number Publication date
CN1465399A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
Eliseeva et al. Vitamin C (ascorbic acid)–description, benefits and where it is found
US6326031B1 (en) Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin
TW491693B (en) Nutritive composition for cardiovascular health
JP3357383B2 (ja) 低分子化植物性組成物
KR20240011214A (ko) 대사질환의 치료 또는 예방용 조성물
EP3165221B1 (en) Blood-fat reducing composition and application thereof
CN105707876B (zh) 一种具有稳定和溶解斑块的饮食组合物及其制备方法和用途
CN114271490A (zh) 一种含sod和麦角硫因的抗疲劳抗氧化和解酒功能的保健配方
JP2008513379A (ja) 高脂血症のためのポリキトサミンとＨＭＧ−ＣｏＡレダクターゼ阻害剤との組み合わせ
WO2020250980A1 (ja) 経口剤、癌抑制補助剤及びペット療法食
CN1282484C (zh) 一种降脂药物组合物
JP6571298B2 (ja) 血糖値スパイク抑制剤、食品及び血糖値スパイク抑制剤の製造方法
DE102006013624B4 (de) Mittel zur Anwendung bei Fructoseintoleranz
CN101669640A (zh) 一种银杏提取物与蜂花粉制备保健食品的方法
CN108771248A (zh) 一种营养丰富的辅助降血脂保健食品及其制备方法
JP4325908B2 (ja) 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物
KR101054808B1 (ko) 폴리감마글루탐산을 함유하는 혈중 콜레스테롤 함량 개선용 조성물
CN103239449A (zh) 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
JP2020100601A (ja) 一酸化窒素合成酵素活性化剤
KR20200107809A (ko) 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제
AU6282796A (en) Fish oil and garlic nutritive composition
JP2001048794A (ja) 桑の葉由来粉末およびカキ由来粉末の混合物を含むｎｉｄｄｍ治療用の医薬組成物および健康食品
Di Folco et al. A Nutraceutical Phytocomplex of Extracts from Citrus Bergamia and Opuntia Ficus-Indica Improves Lipid Profile in Subjects with Mild Hypercholesterolemia: A Pilot Study
CN108652010B (zh) 一种欧米伽3速溶剂及其制备方法
CN111838669B (zh) 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ZHANG KUNYONG; APPLICANT

Free format text: FORMER OWNER: LV YINGZHI

Effective date: 20060707

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Deng Zhiqiang

Inventor after: Dai Chuanfeng

Inventor after: Lv Yingzhi

Inventor after: Zhang Kunyong

Inventor after: Sun Qiyu

Inventor after: Lv Mingming

Inventor before: Lv Yingzhi

Inventor before: Sun Qiyu

Inventor before: Lv Mingming

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LV YINGZHI; SUN QIYU; LV MINGMING TO: DENG ZHIQIANG; LU CHUAN-FENG; LV YINGZHI; ZHANG KUNYONG; SUN QIYU; LV MINGMING

TA01 Transfer of patent application right

Effective date of registration: 20060707

Address after: 250014, Shandong, Ji'nan, No. ten East Road, No. 155, Ji'nan XinDa Patent Office transferred to Lv Yingzhi

Applicant after: Zhang Kunyong

Co-applicant after: Deng Zhiqiang

Co-applicant after: Dai Chuanfeng

Co-applicant after: Lv Yingzhi

Address before: 250014, Shandong, Ji'nan, No. ten, No. 155, Ji'nan XinDa Patent Office transferred to Lv Yingzhi

Applicant before: Lv Yingzhi

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BOWLING BAO BIOLOGY CO., LTD.; ZHANG KUNYONG

Free format text: FORMER OWNER: ZHANG KUNYONG; DENG ZHIQIANG; LU CHUAN-FENG

Effective date: 20081024

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20081024

Address after: 1, East Outer Ring Road, Yucheng hi tech Development Zone, Shandong, zip code: 251200

Co-patentee after: Zhang Kunyong

Patentee after: Bao Bowen biological Limited by Share Ltd

Address before: Shandong province Ji'nan 155 Ji'nan ten East Road XinDa Patent Office Zai Ying Zhi zip: 250014

Co-patentee before: Deng Zhiqiang

Patentee before: Zhang Chi Yong

Co-patentee before: Dai Chuanfeng

ASS Succession or assignment of patent right

Owner name: ZHANG KUNYONG BAOLINGBAO BIOLOGY CO., LTD.

Free format text: FORMER OWNER: ZHANG KUNYONG

Effective date: 20120606

Owner name: CHEN XINGXING

Free format text: FORMER OWNER: BAOLINGBAO BIOLOGY CO., LTD.

Effective date: 20120606

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 251200 DEZHOU, SHANDONG PROVINCE TO: 310012 HANGZHOU, ZHEJIANG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20120606

Address after: Hangzhou City, Zhejiang Province, 310012 Xihu District osmanthus Chunxiao Court Building 102 room 2

Co-patentee after: Zhang Kunyong

Patentee after: Chen Xingxing

Co-patentee after: Baolingbao Biology Co., Ltd.

Address before: The 251200 Shandong Yucheng high tech Development Zone, East Ring Road No. 1

Co-patentee before: Zhang Kunyong

Patentee before: Baolingbao Biology Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061101

Termination date: 20150625

EXPY Termination of patent right or utility model